Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)
Analysts fell to the sidelines weighing in on Amgen (AMGN) and Airsculpt Technologies (AIRS) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen (AMGN)
In a report issued on April 3, Courtney Breen from Bernstein maintained a Hold rating on Amgen. The company’s shares closed last Thursday at $347.94.
According to TipRanks.com, Breen is a 4-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $369.16, representing a 4.7% upside. In a report issued on April 2, Wells Fargo also assigned a Hold rating to the stock with a $390.00 price target.
See the top stocks recommended by analysts >>
Airsculpt Technologies (AIRS)
In a report issued on April 2, Sam Eiber from BTIG maintained a Hold rating on Airsculpt Technologies. The company’s shares closed last Thursday at $3.17, close to its 52-week low of $2.24.
According to TipRanks.com, Eiber is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Airsculpt Technologies.
Read More on AMGN:
Disclaimer & DisclosureReport an Issue
- Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study
- Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next
- Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list
- Zai Lab, Amgen announces trial agreement to evaluate zocilurtatug pelitecan
- FDA identifies cases of serious liver injury in patients taking Tavneos
